Intercept Pharmaceuticals Inc Price/Book
Cos'è Price/Book di Intercept Pharmaceuticals Inc?
Price/Book di Intercept Pharmaceuticals Inc è 4.95
Qual è la definizione di Price/Book?
Il rapporto Price to book rappresenta il rapporto tra il valore delle azioni di una società e il valore contabile per azione.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Price/Book di aziende nel Health Care settore su NASDAQ rispetto a Intercept Pharmaceuticals Inc
Cosa fa Intercept Pharmaceuticals Inc?
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Aziende con price/book simili a Intercept Pharmaceuticals Inc
- HKE ha Price/Book di 4.94
- VanEck Vectors Gold Miners UCITS ETF ha Price/Book di 4.95
- Harrow Health ha Price/Book di 4.95
- Pan Pacific International ha Price/Book di 4.95
- Dolly Varden Silver ha Price/Book di 4.95
- Constellation Brands ha Price/Book di 4.95
- Intercept Pharmaceuticals Inc ha Price/Book di 4.95
- Nestlé SA ha Price/Book di 4.95
- Info Edge (India) ha Price/Book di 4.95
- Kewal Kiran Clothing ha Price/Book di 4.96
- Omai Gold Mines Corp ha Price/Book di 4.96
- Fuse Cobalt Inc ha Price/Book di 4.96
- Sheela Foam ha Price/Book di 4.96